Gitnux/Report 2026

Microbiology Industry Statistics

306Statistics
84Sources
12Sections
1Visuals
49mRead
Microbiology Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The microbiology industry at a glance

The global microbiology and bacterial culture media market was valued at $5.9 billion in 2025 and is forecast to reach $11.8 billion by 2033, supported by diagnostics, biopharmaceutical production, food safety and antimicrobial-resistance testing.

$5.9B[50]
Market size, 2025
9.2%[50]
Forecast CAGR, 2026–2033
38.2%[50]
North America share, 2025
20,100[71]
U.S. microbiologists employed, 2025
Market size
The global microbiology and bacterial culture media market was valued at $5.9 billion in 2025. Grand View Research estimates the market at $6.4 billion in 2026.[50]
Forecast & CAGR
The market is projected to reach $11.8 billion by 2033, representing a 9.2% compound annual growth rate from 2026 to 2033.[50]
Market share & regions
North America held the largest regional share at 38.2% in 2025. Asia-Pacific was identified as the fastest-growing region, driven by expanding healthcare, food and beverage production, biotechnology and laboratory infrastructure.[50]
Segmentation
The market is segmented by product into dehydrated culture media and ready-to-use media. Major applications include pharmaceutical and biopharmaceutical production, diagnostics, food and water testing, bioenergy and agricultural research, cosmetics and personal care, and other uses; pharmaceutical and biopharmaceutical production represented 39.1% of revenue in 2025.[50]
Key players & concentration
Leading suppliers include Thermo Fisher Scientific, BD, Merck KGaA, bioMérieux, HiMedia Laboratories, Neogen and Bio-Rad. Thermo Fisher’s microbiology business generated $645 million in revenue in 2025 and employed approximately 2,400 people across 13 manufacturing and research sites, while the broader market includes numerous regional and specialized suppliers.[50][72][21]
Trends, drivers & challenges
Growth is being supported by infectious-disease diagnosis, antimicrobial-resistance surveillance, biopharmaceutical manufacturing, laboratory automation and food-safety testing. The World Health Organization reported that approximately one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics in 2023, increasing demand for identification and susceptibility testing; access to advanced diagnostics and uneven laboratory capacity remain challenges.[50][73]
M&A
In April 2026, Thermo Fisher agreed to sell its microbiology business to Astorg for approximately $1.075 billion, including a $50 million seller note. The business generated $645 million in 2025 and covers antimicrobial-susceptibility testing and culture-media solutions for clinical, pharmaceutical and food-safety customers.[21][72]
Regulation
Clinical microbiology diagnostics in the European Union are governed by the In Vitro Diagnostic Medical Devices Regulation, Regulation (EU) 2017/746. In 2026, the European Commission published implementation updates covering uniform conformity-assessment requirements and notified bodies, adding compliance requirements for manufacturers and diagnostic developers.[74]
Latest news
The most significant recent transaction is Astorg’s planned acquisition of Thermo Fisher’s global microbiology business, announced on April 27, 2026. The business was expected to become an independent, privately owned platform and operated approximately 13 manufacturing and research sites globally.[72][21]

02 Ranking

Top 10 Companies in the Microbiology Industry

The leading companies in the microbiology industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Roche leads Gitnux's 2026 microbiology ranking with an Overall score of 9.5, with molecular and infectious-disease tests; R&D 19.8% of revenue and revenue growth 7%. Sartorius is the highest-ranked laboratory equipment maker at 9.2, backed by 15.3% operating margin and revenue growth of 4.7%.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in molecular diagnostics

    Roche

    CH

    Ranked #1 · 9.5 · Molecular diagnostics

    Why we picked it: It supports infectious-disease microorganism detection with molecular tests, with R&D at 19.8%.

    See in ranking ↓Visit roche.com ↗

  2. Leader in bioprocess equipment

    Sartorius

    DE

    Ranked #2 · 9.2 · Bioprocess equipment

    Why we picked it: It supplies microbiology fermentation, cultivation, filtration, and lab technologies for bioprocess workflows.

    See in ranking ↓Visit sartorius.com ↗

  3. Leader in clinical microbiology diagnostics

    bioMérieux

    FR

    Ranked #3 · 9.0 · Clinical microbiology diagnostics

    Why we picked it: It focuses on clinical and industrial microbiology diagnostics for microorganism control workflows.

    See in ranking ↓Visit biomerieux.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the microbiology industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Roche

Molecular diagnostics · CH

9.5
2

Sartorius

Bioprocess equipment · DE

9.2
3

bioMérieux

Clinical microbiology diagnostics · FR

9.0
4

QIAGEN

Molecular sample prep · NL

9.0
5

Agilent Technologies

Analytical instruments · US

8.9
6

Danaher

Life-science tools, diagnostics and microbiology · US

8.8
7

Condalab

Microbiological culture media and reagents · ES

8.7
8

Bruker

Microbiology and infection-diagnostics instruments · US

8.2
9

Liofilchem

Clinical and industrial microbiology products · IT

7.8
10

Eppendorf

Microbiology laboratory equipment and consumables · DE

7.7

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the microbiology industry. In Microbiology Industry Statistics. Gitnux. https://gitnux.org/microbiology-industry-statistics/#top-companies

report visual · Projection

Global microbial cultures import market size

Global microbial cultures import market size fell from $8.3B in 2020 to $3.0B in 2024.

$8.3B
Start
-22.37%
CAGR · 4y
$3B
Projected
20202024
source-verifiedgtaic.ai2024

04 Statistics

Technology & Innovation

Validation and lab-automation metrics dominate, including 94.32% sensitivity and 3,844 clinical bacteriology plates in France. Staffing and turnaround shifts also appear, with 8.5 FTE after total automation.

AI in the microbiology industry

  • 94.32% sensitivity was achieved by an AI model detecting Trichomonas vaginalis from routine Gram-stained vaginal smears in a 2026 validation study.[1]
  • 92.28% accuracy was achieved by an AI model identifying Trichomonas vaginalis from routine Gram-stained vaginal smears in a 2026 validation study.[1]
  • 91.97% specificity was achieved by an AI algorithm for bacterial-growth detection at 48 hours in clinical bacteriology plates in France in 2024.[1]
  • 98.80% accuracy was reported for a GoogLeNet convolutional-neural-network model recognizing five microbial colony classes in a 2025 clinical microbiology study.[1]
  • 3,844 clinical bacteriology plates were used to evaluate an AI bacterial-growth monitoring algorithm in France in 2024.[1]
  • 89.86% specificity was achieved by an AI model classifying negative samples in Trichomonas vaginalis smear analysis in 2026.[1]

Automation in the microbiology industry

  • 49 samples per full-time equivalent per day were processed before automation in a Portuguese clinical microbiology laboratory in 2020.[1]
  • 8.5 full-time-equivalent staff were used after total laboratory automation in the same Portuguese clinical microbiology laboratory in 2021.[1]
  • 10 full-time-equivalent staff were used before total laboratory automation in a Portuguese clinical microbiology laboratory in 2020.[1]
  • 492 samples were processed on weekdays before conversion to total automation in a clinical microbiology laboratory in Portugal in 2020.[1]
  • 97% of specimen types considered suitable for automation were processed through total laboratory automation at one clinical microbiology laboratory in 2025.[1]
  • 70.3 hours was the pre-intervention turnaround time for vaginal swabs in a Portuguese laboratory conversion to automation and lean processing.[1]

Digital Transformation in the healthcare services sector (sector benchmark)

  • About 70% of surveyed healthcare executives said investing in technology platforms for digital tools and services would be important or very important in 2025.[2]
  • Among healthcare respondents to KPMG’s global technology survey, 49% were adopting DevSecOps approaches to adapt digital-transformation strategies.[3]
  • Across U.S. non-federal acute care hospitals, 71% used predictive AI integrated into electronic health records in 2024.[4]
  • About 90% of surveyed global healthcare C-suite executives expected digital technology use to accelerate in 2025, including 50% anticipating a significant impact.[2]
  • Across surveyed healthcare practitioners, 60% believed their organizations’ digital experiences met or exceeded customer needs in 2025.[5]

Technology Adoption in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 92% enabled patients to securely message providers in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 99% enabled patients to view health information electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 96% enabled patients to download health information electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 81% enabled patient access through applications using application-programming-interface specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 70% enabled patient access through applications using HL7 FHIR specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 84% enabled patients to transmit health information to a third party electronically in 2024.[4]

Cloud Computing in the healthcare services sector (sector benchmark)

  • Across surveyed healthcare organizations globally, 18% had started adopting cloud services but lacked a comprehensive cloud strategy at the end of 2025.[6]
  • Across surveyed healthcare organizations globally, 15% reported that cloud adoption was fully integrated into business strategy at the end of 2025.[6]
  • Across surveyed healthcare organizations globally, 8% reported minimal cloud adoption without formal strategy or governance at the end of 2025.[6]
  • Across surveyed healthcare organizations globally, 31% had a formal cloud strategy and governance framework that was not yet integrated into IT strategy at the end of 2025.[6]
  • Across surveyed healthcare organizations globally, 27% reported that cloud operations were well managed and integrated into overall IT strategy at the end of 2025.[6]

Big Data in the healthcare services sector (sector benchmark)

  • Across Brazilian healthcare facilities conducting Big Data analytics, 77% used in-house staff rather than external providers in 2024.[7]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 38% used geolocation data from mobile phones, wireless connections, or GPS in 2024.[7]

05 Statistics

Data & Analytics

Integration and analytics adoption stand out, including 71% of medical laboratories using analyzer integration through LIS in 2023. In 2026, 50% cite integration across multiple systems as a data-quality challenge.

Business intelligence in the microbiology industry

  • 35% of Thai clinical microbiology laboratories manually entered patient identifiers into commercial LIMS in 2022.[1]
  • 71% of medical laboratories reported analyzer integration through their LIS in 2023.[8]
  • 73% of medical laboratories used in-house LIS software or servers in 2023.[8]
  • 53% of Thai clinical microbiology laboratories could automatically import patient identifiers from hospital information systems into LIMS in 2022.[1]
  • 28% of medical laboratories used cloud-based LIS infrastructure in 2023.[8]
  • 56% of medical laboratories had electronic billing or revenue-cycle management processes through their LIS in 2023.[8]

Data analytics in the microbiology industry

  • 36% of medical laboratories relied on analytics tools integrated with their LIS in 2026.[9]
  • 27% of medical laboratories used analytics tools that were part of their LIS in 2026.[9]
  • 50% of medical laboratory professionals identified integration across multiple systems as a primary data-quality challenge in 2026.[9]
  • 20% of medical laboratory professionals used third-party business-intelligence platforms in 2026.[9]
  • 28% of medical laboratory professionals used custom-built internal dashboards in 2026.[9]
  • 33% of medical laboratory professionals used instrument-provided analytics for reporting and decision-making in 2026.[9]

Data Quality in the healthcare services sector (sector benchmark)

  • 75% of U.S. healthcare organizations represented in the survey predominantly used clinical registry data for quality and process improvement in 2024.[10]
  • 40% of U.S. healthcare clinical data abstractors reported that manual data entry hampers clinical registry efforts in 2024.[10]
  • 8% of U.S. healthcare organizations rated their provider data as excellent in 2022.[11]
  • 50% of U.S. healthcare clinical data abstractors reported that data inaccuracies hamper clinical registry efforts in 2024.[10]
  • 40% of U.S. healthcare clinical data abstractors reported that incomplete data hampers clinical registry efforts in 2024.[10]

Data Governance in the healthcare services sector (sector benchmark)

  • 38% of healthcare organizations had formal data and information quality-management statements in 2025.[11]
  • 66% of healthcare organizations reported multidisciplinary representation in governance, including patient or consumer representatives, in 2025.[11]
  • 10% of healthcare organizations managed data governance exclusively within IT in 2025.[11]
  • 77% of healthcare organizations reported that their governance functions met at least quarterly in 2025.[11]
  • 72% of healthcare organizations operated governance using approved policy and standards frameworks in 2025.[11]
  • 39% of healthcare organizations reported having a formally chartered data-governance function in 2025.[11]

KPIs in the microbiology industry

  • 37.2% of the vaginal-swab turnaround-time reduction was attributed to automation in the microbiology laboratory.[12]
  • 40.0 hours was the median turnaround time for urine samples after automation and workflow improvement in the microbiology laboratory.[12]
  • 621 samples per weekday were processed after automation in the microbiology laboratory in 2021.[12]
  • 48.2 hours was the median turnaround time for vaginal swabs after automation and workflow improvement in the microbiology laboratory.[12]
  • 73.7 hours was the median turnaround time for urine samples before automation in the microbiology laboratory.[12]
  • 8.5 full-time-equivalent staff supported the microbiology laboratory after automation in 2021.[12]

06 Statistics

Strategy & Growth

Microbiology spending links to connected footprints and site deployment, such as 26,750 BIOFIRE instruments installed by end of 2024. Divestiture scale also appears: $645 million in 2025 microbiology revenue.

Growth in the microbiology industry

  • 6.3% was bioMérieux’s 2025 microbiology growth excluding China, while microbiology instrument sales increased 14%.[13]
  • 14,600 people worked for bioMérieux across 45 operating countries in 2024, supporting its global microbiology and diagnostics strategy.[13]
  • $645 million was Thermo Fisher’s microbiology revenue in 2025, compared with $633 million in 2024 and $618 million in 2023.[14]
  • €3.98 billion was bioMérieux’s consolidated sales in 2024, representing 10.3% organic growth from 2023.[13]
  • 8.3% was bioMérieux’s microbiology sales growth in 2024, driven by reagent volumes and price increases.[13]
  • €638.9 million was bioMérieux’s 2025 industrial-applications revenue, serving industrial microbiology laboratories in food, pharmaceutical and cosmetics markets.[15]

Differentiation in the microbiology industry

  • 16 bioMérieux research and development centers operated in 2024, supporting a geographically distributed innovation model.[13]
  • 20 hours is Sapho Bio’s stated turnaround for its RNA-based rapid sterility assay, compared with the conventional 14-day standard.[16]
  • 2 percentage points was bioMérieux’s microbiology price increase in 2025, supporting differentiation through value-added products and installed systems.[13]
  • 26,750 BIOFIRE instruments were installed globally by the end of 2024, giving bioMérieux a substantial connected diagnostic footprint.[13]
  • 170 employees worked at Infinity Laboratories in Sunnyvale, California, after Eurofins expanded its U.S. microbiology testing footprint through the business.[17]
  • Under 10 minutes is Spore.Bio’s stated detection time for identifying and quantifying living microorganisms with its reagent-free, culture-free platform.[18]

Mergers and acquisitions in the microbiology industry

  • €8 million was bioMérieux’s approximate investment to acquire 100% of Brazil-based Neoprospecta in January 2025.[13]
  • 40 years of anaerobe expertise was added to Biolog through its 2025 acquisition of Anaerobe Systems.[19]
  • October 20, 2026 was the closing date for Mérieux NutriSciences’ acquisition of Certified Group, a food-testing company with core microbiology services.[20]
  • 3 acquisitions had been completed by Biolog by February 2025, when it acquired Anaerobe Systems as its third acquisition.[19]
  • $50 million was the seller-note component of Thermo Fisher’s 2026 divestiture of its microbiology business to Astorg.[21]
  • 1 new country was added to Microbiologics’ operating footprint when it acquired Germany-based SensID in 2024.[22]

Strategic partnerships in the microbiology industry

  • 3 years is the term of QIAGEN’s microbiome-research collaboration with McGill University, launched in November 2024.[23]
  • More than 60% of pathogens identified by Microba’s MetaPanel in IBD flare patients were missed by current routine testing methods.[24]
  • 200 scientists and professional staff worked at Southern Research when it announced its 2026 partnership with Pathogenus Consulting.[24]
  • 500 members and 125 faculty from more than 42 departments participated in Penn State’s One Health Microbiome Center involved in QIAGEN’s 2024 collaboration.[25]
  • 4 antimicrobial-stewardship Centers of Excellence were reached in the United States after bioMérieux and OhioHealth launched a formal partnership in 2025.[13]
  • 3 years is the partnership term between Southern Research and Pathogenus Consulting for international infectious-disease research opportunities.[24]

07 Statistics

People & Workforce

Workforce availability and credentialing show up in multiple figures, including a 5.6% supervisor vacancy rate in 2024. Retirement expectations range up to 26.8% of supervisors within five years.

Hiring in the microbiology industry

  • 5.6% was the supervisor vacancy rate for U.S. microbiology departments in 2024.[26]
  • 52.8% of U.S. microbiology supervisors said certification examinations were prerequisites for hiring candidates in 2024.[26]
  • 68.1% of supervisors in U.S. microbiology departments were credentialed in 2024.[26]
  • 66% of U.S. microbiology job postings in clinical and managerial settings required at least a bachelor’s degree in 2023.[27]
  • 7–12 months was the reported time to fill supervisory microbiology vacancies in U.S. medical laboratories in 2024.[26]

Employee retention in the microbiology industry

  • 14.0% of employees in U.S. microbiology departments were expected to retire within five years in 2024.[26]
  • 14.1% of staff in U.S. microbiology departments were expected to retire within five years in 2022.[26]
  • Microbiology doctorates were more likely to change jobs and employers than chemistry or biochemistry and biophysics doctorates during 2001–2021.[27]
  • 26.8% of supervisors in U.S. microbiology departments were expected to retire within five years in 2024.[26]
  • 12.6% of staff in U.S. microbiology departments were expected to retire within five years in 2024.[26]

Remote Work in the healthcare services sector (sector benchmark)

  • Across U.S. medical groups, 52% reported that 1%–25% of their workforce worked remotely at least 50% of the time.[28]
  • Across U.S. medical groups, 18% of leaders expected their organization’s share of remote or hybrid jobs to decrease during 2024.[28]
  • Across U.S. health care and social assistance, 18% of full-time employees worked fully from home during December 2024–March 2025.[29]
  • Across U.S. medical groups, 22% of leaders expected their organization’s share of remote or hybrid jobs to increase during 2024.[28]

Hybrid Work in the healthcare services sector (sector benchmark)

  • Across U.S. healthcare practitioners and technical roles, 16% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[28]
  • About 12% of nonclinical healthcare administrative and customer-support jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[28]
  • Across U.S. health care and social assistance, 24% of full-time employees were in hybrid arrangements during December 2024–March 2025.[29]
  • Across U.S. healthcare support roles, 14% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[28]
  • About 6% of U.S. healthcare jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[28]

Upskilling in the microbiology industry

  • 117% was the growth in U.S. microbiologist job postings mentioning ribonucleic acid sequencing among the fastest-growing skills from 2019–2022.[27]
  • 107% was the growth in U.S. microbiologist job postings mentioning ASCP certification among the fastest-growing skills from 2019–2022.[27]
  • 37% was the growth in U.S. microbiologist job postings mentioning asepsis among the fastest-growing skills from 2019–2022.[27]
  • 450% was the growth in U.S. microbiologist job postings mentioning RNA extraction among the fastest-growing skills from 2019–2022.[27]
  • 27% was the growth in U.S. microbiologist job postings mentioning pharmaceuticals among the fastest-growing skills from 2019–2022.[27]

Employee Engagement in the healthcare services sector (sector benchmark)

  • U.S. registered nurses with low teamwork scores were 1.53 times more likely to leave their healthcare organization in 2024.[30]
  • Across U.S. healthcare organizations, employee turnover fell from 20% to 18% in 2024.[30]
  • Among U.S. healthcare advanced practice providers, 52% felt heard in 2024.[30]
  • Across 2.3 million U.S. healthcare workers, employee engagement declined by 0.02 points in 2024.[30]
  • Across NHS staff, the national staff-engagement theme score was 6.64 in the second quarter of 2024/25.[31]

DEI in the microbiology industry

  • 76% of respondents to the global ASM 2025 microbiology careers survey resided in the United States.[27]

08 Statistics

Customer & Sales

Customer outcomes rely on retention and satisfaction metrics, including bioMérieux customer-satisfaction at 88% in 2025. Digital ordering also appears in Brazil, with e-commerce share rising to 27.6% in 2025.

Customer experience in the microbiology industry

  • 100% of customers responding to Melbec Microbiology’s latest annual client survey said they would recommend the company, according to the UK microbiology laboratory.[32]
  • 96.7% of bioMérieux clinical and industrial customers surveyed across 43 countries reported satisfaction in 2021.[33]
  • 88% was bioMérieux’s global customer-satisfaction score in 2025, based on responses from nearly 9,500 active customers worldwide.[13]
  • 100% of 15 surveyed health-product customers in the first half of 2024 were very satisfied or satisfied with Microbio’s products and services in Taiwan.[34]
  • 100% of 12 surveyed pharmaceutical clients were very satisfied or satisfied with Microbio in 2024, with a 100% questionnaire response rate.[34]

Customer retention in the microbiology industry

  • 97.1% was IDEXX’s U.S. customer-revenue retention rate for Rapid Assay in 2022.[35]
  • 13.61% of customers in the Brazilian microbiology division’s 2021–2025 database were classified as late digital transformation, representing 479 customers.[36]
  • 99.0% was IDEXX’s U.S. customer-revenue retention rate for Catalyst consumables in 2022, a microbiology-adjacent diagnostics consumables category.[35]
  • 6.79% of customers in the Brazilian microbiology division’s 2021–2025 database were classified as undergoing digital transformation, representing 239 customers.[36]
  • 97.5% was IDEXX’s U.S. customer-revenue retention rate for reference-laboratory services in 2022.[35]

Customer acquisition in the microbiology industry

  • 27.3% of orders in the Brazilian microbiology division were placed through e-commerce in 2021, calculated from 4,340 digital orders out of 15,880 total orders.[36]
  • 27.6% of orders in the Brazilian microbiology division were placed through e-commerce in 2025, calculated from 5,459 digital orders out of 16,144 total orders.[36]
  • 47.6% was the increase in e-commerce order volume in the Brazilian microbiology division between 2021 and 2025, rising from 4,340 to 5,459 orders.[36]
  • 16,144 orders were recorded in the Brazilian microbiology division in 2025, comprising 10,685 offline orders and 5,459 e-commerce orders.[36]
  • 15,880 orders were recorded in the Brazilian microbiology division in 2021, comprising 11,540 offline orders and 4,340 e-commerce orders.[36]

Customer loyalty in the microbiology industry

  • 96.9% was IDEXX’s U.S. customer-revenue retention rate for Rapid Assay in 2017.[35]
  • 98.2% was IDEXX’s U.S. customer-revenue retention rate for Catalyst consumables in 2017.[35]
  • 99% or more was IDEXX’s reported customer-retention level for its water microbiology testing business in 2023.[37]
  • 96.9% was IDEXX’s U.S. customer-revenue retention rate for reference-laboratory services in 2017.[35]
  • 100% of respondents to Melbec Microbiology’s latest annual client survey said they would recommend the UK microbiology laboratory.[32]

09 Statistics

Marketing & Brand

Market sizing and channel indicators appear alongside event and social-media figures. For example, the estimated global clinical microbiology market was €3 billion in 2023 with 10% growth.

Marketing in the microbiology industry

  • €3 billion was the estimated global clinical microbiology market in 2023, according to bioMérieux and IQVIA MedTech.[13]
  • 10% was the estimated 2023 growth rate of the global clinical microbiology market.[13]
  • 40% was bioMérieux’s estimated global clinical microbiology market share in 2023.[13]
  • €3 billion was the estimated global industrial in-vitro diagnostics market in 2023, including microbiological quality-control applications worldwide.[13]
  • 75% was bioMérieux’s estimated market share for multiplex infectious-disease testing through its BIOFIRE range at the end of 2023.[13]

Digital marketing in the microbiology industry

  • 29% of #microMOOCSEM followers were located in Mexico, Venezuela, Argentina, Colombia, Peru, or Chile during the course.[1]
  • 62% of #microMOOCSEM followers were located in Spain during the Spanish Society for Microbiology’s Twitter course.[1]
  • 4,420,172 Twitter impressions were generated by the Spanish Society for Microbiology’s #microMOOCSEM course.[1]
  • 61% of followers were female during the Spanish Society for Microbiology’s #microMOOCSEM Twitter course.[1]
  • 2,176 followers were recorded for the Spanish Society for Microbiology account before the #microMOOCSEM course began.[1]

Branding in the microbiology industry

  • 80% of Microbiology Society Annual Conference delegates came from the UK, defining the event’s principal geographic audience for exhibitor branding.[38]
  • 73.2% of Microbiology Society Annual Conference delegates were from universities, the largest audience segment for exhibitor brand exposure.[38]
  • 95% of exhibitors rated the Microbiology Society Annual Conference excellent or good, indicating strong event-brand satisfaction among microbiology exhibitors.[38]

Social media in the microbiology industry

  • More than 175,000 visits were recorded for the Spanish Society for Microbiology Twitter account during #microMOOCSEM.[1]
  • 1,334 contributors generated social-media activity during the Microbiology Society’s 2021 Annual Conference Online.[38]
  • 13,900 followers were reported for the @AntibioticResis microbiology-focused Twitter account in a social-media analysis.[1]
  • 51,000-plus LinkedIn followers were reported for the Microbiology Society in 2023.[38]
  • More than 1,200 followers were reported for the Pseudomonas-focused @pseudo_papers microbiology Twitter bot.[1]

Influencer Marketing in the healthcare services sector (sector benchmark)

  • 50% of U.S. physicians surveyed had changed prescribing choices based on healthcare influencer or KOL content on social media in 2024.[39]
  • 33% of U.S.-focused health and wellness influencers promoted a product, service or subscription in more than half of their posts in 2026.[40]
  • 50% of healthcare and pharmaceutical marketers reported dedicated, growing creator/influencer budgets in 2026, compared with 58% globally.[41]
  • 8.57 million influencer posts about the health industry generated a 1.07% average engagement rate globally in 2023.[42]
  • 92% of U.S.-focused health and wellness influencers included product or service promotions at least occasionally in 2026.[40]

10 Statistics

Operations & Execution

Operational performance changes track automation and consolidation. In a Belgian lab, 621 samples per weekday were processed after automation while staffing fell to 8.5 FTEs.

Process optimization in the microbiology industry

  • 14 hours was the median turnaround-time reduction after full laboratory automation across four North American microbiology laboratories in 2020.[12]
  • 110 samples per FTE per day were projected after continuous-improvement events in a Belgian clinical microbiology laboratory in 2021.[12]
  • 73.7 hours was the median urine turnaround time before automation, compared with 40.0 hours afterward, in Belgium in 2021.[12]
  • 49 samples per FTE per day were processed before automation in a Belgian clinical microbiology laboratory in 2020.[12]
  • 621 samples per weekday were processed after automation, while staffing fell to 8.5 FTEs in the same Belgian microbiology laboratory in 2021.[12]

Operational efficiency in the microbiology industry

  • 4,390,741 microbiology tests were processed by Dubai Health’s central laboratory in the United Arab Emirates in 2024.[1]
  • 25% was the projected efficiency improvement from additional automation at Dubai Health’s microbiology laboratory in the United Arab Emirates in 2024.[1]
  • 97% of non-critical samples reached Dubai Health’s central microbiology laboratory within the two-hour transport target in the United Arab Emirates in 2024.[1]
  • 20% was the reduction in manual handling after microbiology-service consolidation at Dubai Health in the United Arab Emirates in 2024.[1]
  • 4% of urine cultures were ready for reading during unscheduled overnight hours after extended culture-reading coverage at one North American laboratory in 2020.[12]

Quality management in the microbiology industry

  • 16% was the pre-intervention blood-culture contamination rate in a microbiology laboratory quality-improvement study reviewed in 2025.[43]
  • 92% of turnaround-time targets were achieved after quality-system implementation in a microbiology laboratory study reviewed in 2025.[43]
  • 23.6% was the pre-implementation liquid-culture contamination rate in a microbiology laboratory quality-improvement study reviewed in 2025.[43]
  • 8.1% of negative controls showed DNA contamination after intervention in the same microbiology quality-improvement study reviewed in 2025.[43]
  • 4% was the post-intervention blood-culture contamination rate in the same microbiology laboratory quality-improvement study reviewed in 2025.[43]

Supply chain in the microbiology industry

  • 62.5% of surveyed laboratories reported reagent shortages in December 2022 during a U.S. clinical-laboratory pandemic survey.[26]
  • 15% of surveyed U.S. medical laboratories said they had adequate testing supplies to meet demand in 2022.[44]
  • 74% of surveyed U.S. medical laboratories reported difficulty sourcing blood-collection tubes because of supply-chain issues in 2022.[44]
  • 20% of surveyed U.S. medical laboratories reported difficulty sourcing pipettes in 2022.[44]
  • 48% of surveyed U.S. medical laboratories reported difficulty sourcing winged blood-collection sets in 2022.[44]

Outsourcing / Offshoring in the healthcare services sector (sector benchmark)

  • 18% of U.S. medical-group leaders planned to outsource or automate patient communications in contact centers in 2024, according to an MGMA poll with 262 responses.[28]
  • 43% of global healthcare providers used third-party providers for payroll services in 2024, based on a survey of 28 healthcare-provider executives.[45]
  • 20% of U.S. medical-group leaders planned to outsource or automate some revenue-cycle-management activities in 2024, according to an MGMA poll with 262 responses.[28]
  • 29% of global healthcare providers used third-party providers for remote patient monitoring in 2024, based on a survey of 28 healthcare-provider executives.[45]
  • 46% of global healthcare providers used third-party providers for customer-experience services in 2024, based on a survey of 28 healthcare-provider executives.[45]

11 Statistics

Finance & Pricing

Profitability and platform economics appear, including bioMérieux operating targets and SPOTFIRE sales. SPOTFIRE revenue reached €95 million in 2024, exceeding a €80 million target.

Pricing strategy in the microbiology industry

  • 3,000 SPOTFIRE instruments were installed globally by the end of 2024, supporting an instrument-and-consumables pricing model.[13]
  • 12% was the 2024 sales increase for bioMérieux’s BIOFIRE respiratory panels, reflecting demand for syndromic microbiology testing.[13]
  • €95 million was bioMérieux’s 2024 annual sales from SPOTFIRE, a microbiology-related diagnostic platform, exceeding its €80 million target.[13]
  • €80 million was bioMérieux’s 2024 SPOTFIRE sales target, illustrating a planned price-and-volume objective for a microbiology-related platform.[13]
  • 15% of bioMérieux’s 2024 sales came from industrial applications, including food and pharmaceutical microbiological control.[13]

Cost reduction in the microbiology industry

  • €15,212.22 was the estimated annual saving from automation across HIV and COVT–COVIDIGG testing in 2022.[46]
  • 65.9% was the improvement in average daily laboratory productivity, rising from 171 to 284 tests per full-time equivalent.[46]
  • €0.14 per test was the reduction in COVT–COVIDIGG testing cost after automation in the studied microbiology laboratory.[46]
  • 21.7% was the reduction in total waiting time for the studied automated serology workflow.[46]
  • 10.6% was the reduction in average HIV serology testing cost after lean methods and total laboratory automation in a microbiology laboratory.[46]

Profitability in the microbiology industry

  • 20% is bioMérieux’s targeted contributive operating margin for 2028 under its GO•28 plan.[13]
  • 8.3% was the 2024 constant-exchange-rate-and-scope growth in bioMérieux microbiology sales.[13]
  • €673 million was bioMérieux’s 2024 contributive operating income before non-recurring items.[13]
  • 7% is bioMérieux’s targeted annual sales growth rate at constant exchange rates and scope for 2024–2028.[13]
  • 10% is bioMérieux’s minimum targeted 2025 growth rate for contributive operating income before non-recurring items.[13]

Financial planning in the microbiology industry

  • 46.6% of surveyed plant diagnostic microbiology laboratories reported no change in funding from January 2021 through 2024.[47]
  • 89% of responding National Plant Diagnostic Network laboratories were located at land-grant universities.[47]
  • 72% of surveyed plant diagnostic microbiology laboratories reported unchanged or decreased revenue over the survey period.[47]
  • 23.3% of surveyed plant diagnostic microbiology laboratories reported increased funding from January 2021 through 2024.[47]
  • 86.3% of surveyed plant diagnostic microbiology laboratories reported higher operating costs from January 2021 through 2024.[47]

12 Statistics

Product & Service

Installed base and service economics recur, including 3,000 SPOTFIRE instruments installed globally by end of 2024. Equipment maintenance capacity varies, with 74% of equipment types having local maintenance and calibration competencies.

Product development in the microbiology industry

  • 7 VITEK MS PRIME panels were available worldwide under bioMérieux’s 2024–2028 development plan.[48]
  • €20 million in SPOTFIRE sales and about 1,200 systems installed worldwide were reported in the first quarter of 2024.[49]
  • +10% is bioMérieux’s targeted 2024–2028 compound annual growth rate for BIOFIRE non-respiratory panels.[48]
  • +7% to +9% is bioMérieux’s targeted 2024–2028 compound annual growth rate for industrial microbiology applications.[48]
  • €95 million in SPOTFIRE sales and 3,000 instruments installed worldwide in 2024, reflecting bioMérieux’s molecular point-of-care product development progress.[13]

Product lifecycle in the microbiology industry

  • The bacterial segment held 53.78% of the global microbiology culture market in 2024.[50]
  • US$250 million in service-contract revenue was estimated for the global MALDI-TOF installed base in 2020.[51]
  • 1,200 MALDI-TOF MS systems were installed worldwide in 2013, compared with approximately 7,200 systems in 2020.[51]
  • 3,400 annual Bruker Biotyper service contracts were reported for 2019 in the cited commercial-impact assessment.[51]
  • 3,800 Bruker Biotyper systems were installed worldwide by 2020, including approximately 3,000 installations since 2013.[51]

After-sales in the microbiology industry

  • 25.8% of laboratory equipment was out of service in low- and lower-middle-income countries.[52]
  • 74% of equipment types had maintenance and calibration competencies available locally worldwide.[52]
  • 47% of equipment types had local maintenance and calibration competencies in Africa.[52]
  • 58% of laboratories were satisfied with external laboratory-equipment service providers in the CDC study.[52]
  • 10% of equipment types had in-house maintenance and calibration competencies in Africa.[52]

Value proposition in the microbiology industry

  • +9% was bioMérieux’s microbiology sales growth in the first quarter of 2024.[49]
  • US$1.91 billion was the estimated U.S. microbiology and bacterial culture-media market size in 2024.[50]
  • €980.8 million was bioMérieux’s microbiology revenue for the first nine months of 2024.[53]
  • 12% growth in microbiology reagent sales was reported by bioMérieux for the first nine months of 2024.[53]
  • €606 million was bioMérieux’s industrial-applications revenue in 2024, covering industrial microbiology customers.[48]

13 Statistics

Sustainability & Ethics

Environmental and compliance actions are quantified, such as Microbio reducing Scope 1 and Scope 2 emissions by 3.8% in 2025 versus 2024. Waste-recycling volume increased to 80.53 tonnes in 2025.

Sustainability in the microbiology industry

  • 91.7% of clinical laboratories in Pakistan used electronic reporting in 2025.[1]
  • 50% of clinical laboratories in Pakistan had fully transitioned to electronic medical records in 2025.[1]
  • 83.3% of clinical laboratories in Pakistan conducted waste audits in 2025.[1]
  • 41.7% of clinical laboratories in Pakistan had a formal or informal sustainability policy in 2025.[1]
  • 66.7% of clinical laboratories in Pakistan used environmentally friendlier chemicals in 2025.[1]

ESG in the microbiology industry

  • Microbio reported NT$1.894 billion in consolidated revenue for fiscal 2025.[34]
  • Microbio’s first-line management workforce was 77% female in 2025.[34]
  • Microbio reported average training of 15.47 hours per full-time employee in 2025.[34]
  • Microbio had zero major trade-secret leakage cases from 2023 through 2025.[34]
  • Microbio and its subsidiaries offered 318 internal education and training courses in 2025.[34]

Ethics in the microbiology industry

  • Microbio’s regulatory-compliance training reached 35.2% completion among headquarters employees in 2025.[34]
  • Microbio trained 289 employees for 726 hours on ethical corporate management and compliance in 2025.[34]
  • Cotton Field Organic’s regulatory-compliance training reached 42.3% completion in 2025.[34]
  • 45% of medical-technology industry associations in the APEC sample had an ethics code or commitment in 2012.[54]
  • 91% of medical-technology industry associations in the APEC sample had a code or code commitment for ethical business practices in 2022.[54]

CSR in the microbiology industry

  • Microbio donated NT$600,000 to the BOYO Social Welfare Foundation in 2025.[34]
  • Microbio employed 149 people directly at December 31, 2025.[34]
  • Microbio spent NT$664,813 on employee training across the group in 2025.[34]
  • Microbio sold 12,464,708 health-supplement and organic-food units in fiscal 2025.[34]
  • Cotton Field Organic cumulatively donated more than 1,000 healthy Chinese New Year dishes to childcare institutions by 2025.[34]

Circular economy in the microbiology industry

  • 58.3% of Pakistani clinical laboratories consolidated samples to reduce collection-tube and reagent use in 2025.[1]
  • Microbio’s general-waste recycling increased to 80.53 tonnes in 2025 from 61.2 tonnes in 2024.[34]
  • 33.3% of Pakistani clinical laboratories regularly audited tests to eliminate outdated or unnecessary requests in 2025.[1]
  • 8.3% of clinical laboratories in Pakistan recycled selected organic solvents on-site in 2025.[1]
  • 91.7% of clinical laboratories in Pakistan reused biological samples or reagents for education or research in 2025.[1]

Carbon footprint in the microbiology industry

  • 259 million tCO2e of 2023 biotech and pharmaceutical emissions came from publicly listed companies.[55]
  • 79% of Scope 3 emissions for biotech and pharmaceutical companies with highest-quality data came from purchased goods and services in 2023.[55]
  • Asia-Pacific biotech and pharmaceutical companies averaged 122.62 tCO2e per million dollars of revenue for Scope 1 and 2 in 2023.[55]
  • The replacement chiller at Microbio’s Longtan Plant was estimated to reduce emissions by 51.046 tCO2e annually.[34]
  • Microbio reduced Scope 1 and Scope 2 emissions by 3.8% in 2025 compared with 2024.[34]

15 Statistics

Globalization & Expansion

Geographic footprint and supply networks appear, including Thermo Fisher’s microbiology distribution network covering 230 countries in 2024. Merck Life Science revenue also shows regional splits: 35% from North America in 2024.

Globalization in the microbiology industry

  • 35% of Merck Life Science revenue came from North America in 2024, equal to €3,146 million.[66]
  • 20% was bioMérieux’s estimated share of the relatively fragmented worldwide industrial microbiology market in 2023.[13]
  • 24% of Merck Life Science revenue came from Asia-Pacific in 2024, equal to €2,143 million.[66]
  • €8,916 million was Merck Life Science revenue in 2024 across Europe, North America, Asia-Pacific, Latin America, and the Middle East and Africa.[66]
  • 40% was bioMérieux’s estimated worldwide clinical microbiology market share in 2023.[13]

Cultural adaptation in the microbiology industry

  • bioMérieux stated that its product portfolio was tailored to specific regional and local needs while systems were marketed under identical trademarks worldwide in 2023.[13]
  • 13.5% was Merck Life Science’s organic revenue growth in Latin America in 2024, the strongest growth among its reported regions.[66]
  • €382 million was Merck Life Science revenue in Latin America in 2024, representing 4% of the business’s regional sales.[66]
  • 8.3% was bioMérieux microbiology sales growth in 2024, driven by reagent volumes and price increases across its markets.[13]
  • €109 million was Merck Life Science revenue in the Middle East and Africa in 2024, representing 1% of the business total.[66]

Supplier management in the microbiology industry

  • Illumina’s global supply chain included suppliers, subcontractors, channel partners, manufacturing sites, distribution centers and customers in 2025.[67]
  • Illumina classified suppliers by categories, segments and subcategories, including strategic suppliers, in 2025.[67]
  • Thermo Fisher reported that no single supplier was material to the company in 2024, although some materials came from single or limited suppliers.[68]
  • bioMérieux used supplier CSR-maturity assessment tools as part of its partner-management practices in 2024.[13]
  • More than 6,100 suppliers in over 70 countries supported QIAGEN’s global operations in 2023 with chemicals, bioreagents, plastics, packaging and services.[53]

Stakeholder management in the microbiology industry

  • €95 million was bioMérieux’s 2024 annual sales from BIOFIRE SPOTFIRE, a platform aimed at office-based and near-patient care.[13]
  • 230 countries were covered by Thermo Fisher’s microbiology distribution network in 2024.[69]
  • €330.4 million was bioMérieux industrial-applications sales in the first half of 2026, according to an industry report citing company results.[70]
  • 13 manufacturing facilities supported Thermo Fisher’s global microbiology distribution network in 2024.[69]
  • 3,000 BIOFIRE SPOTFIRE instruments had been installed by the end of 2024, expanding access to decentralized infectious-disease testing.[13]

Distribution channels in the microbiology industry

  • More than 30 countries were covered by QIAGEN’s direct distribution network in 2023.[53]
  • More than 170 countries were supplied by QIAGEN’s international sales and distribution operations in 2024.[25]
  • Illumina’s supply chain included channel partners and distribution centers as distinct links between suppliers, manufacturing and customers in 2025.[67]
  • 2.3 million product lines were shipped annually through Thermo Fisher’s microbiology distribution network in 2024.[69]
  • Illumina described a global channel-partner network that provided sales, marketing, service and customer support in 2025.[67]

Key questions about the microbiology industry

What is the global microbiology and bacterial culture media market size in 2025?
The global microbiology and bacterial culture media market was valued at $5.9 billion in 2025.
How fast is the microbiology and bacterial culture media market expected to grow from 2026 to 2033?
The market is forecast to reach $11.8 billion by 2033, with a 9.2% CAGR from 2026 to 2033.
Which companies lead the microbiology industry?
Roche leads Gitnux's 2026 microbiology ranking with an Overall score of 9.5, with molecular and infectious-disease tests; R&D 19.8% of revenue and revenue growth 7%. Sartorius is the highest-ranked laboratory equipment maker at 9.2, backed by 15.3% operating margin and revenue growth of 4.7%.
What technology shifts are showing up in microbiology workflows?
Automation and lab analytics are visible in the data, including 8.5 full-time-equivalent staff after total laboratory automation in 2021 versus 10 before automation in 2020.
How is the market structured by product and application?
Product segmentation includes dehydrated culture media and ready-to-use media; pharmaceutical and biopharmaceutical production represented 39.1% of revenue in 2025.
What compliance change affects clinical microbiology diagnostics in the EU in 2026?
In 2026, the European Commission published implementation updates under the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 covering uniform conformity-assessment requirements.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Microbiology Industry Statistics. Gitnux. https://gitnux.org/microbiology-industry-statistics
MLA
Samuel Norberg. "Microbiology Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/microbiology-industry-statistics.
Chicago
Samuel Norberg. 2026. "Microbiology Industry Statistics." Gitnux. https://gitnux.org/microbiology-industry-statistics.

Sources & references

84 sources cited across this report

  1. pmc.ncbi.nlm.nih.gov
  2. deloitte.com
  3. kpmg.com
  4. healthit.gov
  5. business.adobe.com
  6. go.rackspace.com
  7. cetic.br
  8. base.imgix.net
  9. mlo-online.com
  10. carta.healthcare
  11. intersystems.com
  12. journals.asm.org
  13. biomerieux.com
  14. stocktitan.net
  15. uk.marketscreener.com
  16. saphobio.com
  17. cdnmedia.eurofins.com
  18. spore.bio
  19. accessnewswire.com
  20. hl.com
  21. ir.thermofisher.com
  22. biospace.com
  23. corporate.qiagen.com
  24. businesswire.com
  25. qiagen.com
  26. academic.oup.com
  27. asm.org
  28. mgma.com
  29. wfhresearch.com
  30. pressganey.com
  31. england.nhs.uk
  32. melbecmicrobiology.co.uk
  33. annualreports.com
  34. twmicrobio.com
  35. idexx.com
  36. revistaes.com.br
  37. stockanalysis.com
  38. microbiologysociety.org
  39. sermo.com
  40. pewresearch.org
  41. brand-news.it
  42. media.sproutsocial.com
  43. degruyterbrill.com
  44. img.mlo-online.com
  45. tcs.com
  46. zaguan.unizar.es
  47. npdn.org
  48. marketscreener.com
  49. webdisclosure.com
  50. grandviewresearch.com
  51. results2021.ref.ac.uk
  52. stacks.cdc.gov
  53. financialfilings.com
  54. apec.org
  55. mygreenlab.org
  56. frontiersin.org
  57. qualio.com
  58. ache.org
  59. ponemonsullivanreport.com
  60. proofpoint.com
  61. kff.org
  62. hfmmagazine.com
  63. sophos.com
  64. news.crunchbase.com
  65. bioindustry.org
  66. reports.emdgroup.com
  67. illumina.com
  68. corporate.thermofisher.com
  69. documents.thermofisher.com
  70. nexchemintelligence.com
  71. bls.gov
  72. astorg.com
  73. who.int
  74. health.ec.europa.eu
  75. roche.com
  76. sartorius.com
  77. agilent.com
  78. danaher.com
  79. condalab.ph
  80. sec.gov
  81. liofilchem.com
  82. eppendorf.com
  83. giiresearch.com
  84. fda.gov